Assessment of adverse events related to anti-influenza neuraminidase inhibitors using the FDA adverse event reporting system and online patient reviews
Open Access
- 20 February 2020
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 10 (1) , 1-8
Abstract
The recommended antiviral drugs available for the treatment and prevention of influenza are neuraminidase inhibitors (NAIs). The aim of this study was to evaluate age-related clinical manifestations of adverse events (AEs) related to NAIs. FAERS and WebMD data were downloaded. The available NAIs selected for the analysis were oseltamivir, peramivir, zanamivir, and laninamivir. Disproportionality was analyzed using the proportional reporting ratio (PRR), the reporting odds ratio (ROR), and the information component (IC) methods. In total, 16729 AEs from 4598 patients and 575 AEs from 440 patients in the FAERS and WebMD, respectively, were included in the analysis. In the FAERS, AEs were more common among those who were younger (65 years) for peramivir. A disproportionality analysis showed that signals for vomiting and hallucinations were detected in younger patients given oseltamivir, while an abnormal hepatic function, cardiac failure, shock, and cardio-respiratory arrest were detected in older patients given peramivir. Psychiatric disorders were most common in younger and older patients, while gastrointestinal disorders were most common in adult given oseltamivir in the WebMD. Adverse symptoms related to NAIs varied and depended on the drugs used and the age of the patient.Keywords
Funding Information
- the National Research Foundation of Korea grant funded by the Korea government (MSIT)
- the National Research Foundation of Korea grant funded by the Korea government (MSIT)
This publication has 35 references indexed in Scilit:
- Data Mining of the Public Version of the FDA Adverse Event Reporting SystemInternational Journal of Medical Sciences, 2013
- Comparison of efficacy and safety of oseltamivir and zanamivir in pandemic influenza treatmentIndian Journal of Pharmacology, 2012
- Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance databaseBritish Journal of Clinical Pharmacology, 2011
- Possible Neuropsychiatric Reaction to High‐Dose Oseltamivir during Acute 2009 H1N1 Influenza A InfectionClinical Infectious Diseases, 2010
- Oseltamivir (Tamiflu) Induced Depressive Episode in a Female AdolescentPsychiatry Investigation, 2010
- Neuroexcitatory actions of Tamiflu and its carboxylate metaboliteNeuroscience Letters, 2007
- Applying quantitative methods for detecting new drug safety signals in pharmacovigilance national databasePharmacoepidemiology and Drug Safety, 2007
- A nonsynonymous SNP in human cytosolic sialidase in a small Asian population results in reduced enzyme activity: potential link with severe adverse reactions to oseltamivirCell Research, 2007
- Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reportsPharmacoepidemiology and Drug Safety, 2001
- The Medical Dictionary for Regulatory Activities (MedDRA)Drug Safety, 1999